NCT04070794 - Food-effect Bioavailability of Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg Under Fed and Fasting Conditions | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2019

Primary Completion Date

November 30, 2019

Study Completion Date

December 30, 2019

Conditions

Type2 Diabetes

Interventions

DRUG

Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fasting)

Fasting conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water after an overnight fasting for at least 8 hours.

DRUG

Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fed)

Fed conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water at 30 minutes after the start of standardized HFHC breakfast.